Key result
Nitroprusside linked to decreased regional myocardial blood flow in CAD, unlike nitroglycerin.
Why the study?
Does nitroprusside affect regional myocardial blood flow differently than nitroglycerin in patients with coronary artery disease?
Observational (n=25)
Does nitroprusside affect regional myocardial blood flow differently than nitroglycerin in patients with coronary artery disease?
Nitroprusside decreases regional myocardial blood flow in CAD patients, potentially worsening ischemia, unlike nitroglycerin which increases flow in those with collaterals.
Nitroprusside may reduce RMBF in CAD; leaves open net clinical effects and requires prospective validation.
The effect of nitroprusside on regional myocardial specific blood flow (RMBF) was evaluated in 25 patients with the xenon-133 washout technique. Six patients were normal (group 1), six patients had coronary artery disease without collateral vessels (group 2), and thirteen patients had coronary artery disease with collateral vessels (group 3). In group 1, RMBF was unchanged following nitroprusside. RMBF decreased significantly in both group 2 and group 3, including seven patients in group 3 with high-grade collateral vessels. The results were compared to the effect of nitroglycerin in 31 patients previously studied using the same technique. Mean arterial pressure and pressure-rate product were comparably reduced by both drugs. In contrast to the findings with nitroprusside, after sublingual nitroglycerin RMBF decreased markedly in normals and increased in patients with coronary artery disease and high-grade collaterals. The data suggest that nitroprusside may primarily affect resistance vessels within the coronary circulation, as opposed to the effect of nitroglycerin on conductance vessels. Thus, nitroprusside could result in redistribution of blood flow away from ischemic areas and potentially increase ischemic injury in some patients with coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Mann et al. (1978) conducted an observational in Coronary artery disease (n=25). Nitroprusside vs. Nitroglycerin was evaluated on Regional myocardial specific blood flow (RMBF). Nitroprusside significantly decreased regional myocardial blood flow in patients with coronary artery disease, in contrast to nitroglycerin which increased flow in patients with high-grade collaterals.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: